Lung cancer research explores immunotherapy efficacy and blood biomarkers

Recent medical research is exploring ways to optimize immunotherapy for patients with resectable non-small cell lung cancer. An observational study of 145 patients examined whether continuing immunotherapy for approximately one year after surgery provides additional benefits for those who achieved a complete pathological response following preoperative chemotherapy and immunotherapy.

The study found no significant difference in disease-free survival or overall survival between patients who continued immunotherapy post-surgery and those who did not. These results remained consistent across various subgroups, including age, sex, and clinical stage, suggesting that for patients who respond exceptionally well to initial treatment, additional postoperative immunotherapy may not offer a clear advantage.

Complementary research published in Nature Cancer, led by Manuel Provencio, is investigating blood-based biomarkers to better predict which patients will benefit most from perioperative immunotherapy, such as nivolumab. Because blood samples are less invasive and easier to collect repeatedly than tumor biopsies, these biological signals could eventually help clinicians implement precision medicine, ensuring patients receive effective treatments while avoiding unnecessary interventions.